"Efficacy of interferon and Amantadin for treatment of hepatitis in major thalasemia at Children’s Medical Center, Tehran "

Background: Major thalassemia is relatively common in Iran and in looking of their need to recurrent transfusion; their high risk for acquisition of HCV is revealed. These patients also suffer form liver hemosiderosis that accelerate disease excursion to cirrhosis and hepatocellular carcinoma. In th...

Full description

Bibliographic Details
Main Authors: Fallahi GHI, Ezadyar M, Fathi A
Format: Article
Language:fas
Published: Tehran University of Medical Sciences 2007-04-01
Series:Tehran University Medical Journal
Subjects:
Online Access:http://journals.tums.ac.ir/PdfMed.aspx?pdf_med=/upload_files/pdf/3244.pdf&manuscript_id=3244
_version_ 1818963481723928576
author Fallahi GHI
Ezadyar M
Fathi A
author_facet Fallahi GHI
Ezadyar M
Fathi A
author_sort Fallahi GHI
collection DOAJ
description Background: Major thalassemia is relatively common in Iran and in looking of their need to recurrent transfusion; their high risk for acquisition of HCV is revealed. These patients also suffer form liver hemosiderosis that accelerate disease excursion to cirrhosis and hepatocellular carcinoma. In this study combined therapy with interferon and amantadin has been evaluated. Methods: This prospective clinical trail has been done on thalasemic patients that had been contaminated by HCV and had laboratory signs of hepatitis. During years of 81-82, 26 patients admitted at Children Mmedical Center with major thalassemia and HCV hepatitis. Inclusion criteria were positive HCV-RNA, high ALT and histologic evidence of hepatitis in liver biopsy and exclusion criteria were history of incomplete treatment any contraindication of IFN or amantadin-emergence of drugs adverse reactions, to intending of these criteria 10 case of them had situation for treatment and follow-up. Results: In 10 cases, treatment with IFN  - 2b in doses 3 mu for every square meter of body surface three times in week subcutaneously and cap. Amantadin in doses 100 mg po B.d for 6 months was done and after it, 8 cases were negative for HCV-RNA (8%) and in 6 patients, ALT turned to normal (60%) and in 2 other case ALT decrease to lower than 50% of pretreatment value. None of them showed drug adverse reactions and response to therapy was better in lower ages. No relation between response to therapy and liver hemosiderosis, inflammation and sexuality was found. Conclusion: Combined therapy with IFN and Amantadin is effective in HCV treatment and for lower recurrence, treatment period longer than 24 wk, such as 48 wk is recommended
first_indexed 2024-12-20T12:45:54Z
format Article
id doaj.art-acfa9b1ab0434918ba1405f8ea416233
institution Directory Open Access Journal
issn 1683-1764
1735-7322
language fas
last_indexed 2024-12-20T12:45:54Z
publishDate 2007-04-01
publisher Tehran University of Medical Sciences
record_format Article
series Tehran University Medical Journal
spelling doaj.art-acfa9b1ab0434918ba1405f8ea4162332022-12-21T19:40:19ZfasTehran University of Medical SciencesTehran University Medical Journal1683-17641735-73222007-04-0164103943"Efficacy of interferon and Amantadin for treatment of hepatitis in major thalasemia at Children’s Medical Center, Tehran "Fallahi GHIEzadyar MFathi ABackground: Major thalassemia is relatively common in Iran and in looking of their need to recurrent transfusion; their high risk for acquisition of HCV is revealed. These patients also suffer form liver hemosiderosis that accelerate disease excursion to cirrhosis and hepatocellular carcinoma. In this study combined therapy with interferon and amantadin has been evaluated. Methods: This prospective clinical trail has been done on thalasemic patients that had been contaminated by HCV and had laboratory signs of hepatitis. During years of 81-82, 26 patients admitted at Children Mmedical Center with major thalassemia and HCV hepatitis. Inclusion criteria were positive HCV-RNA, high ALT and histologic evidence of hepatitis in liver biopsy and exclusion criteria were history of incomplete treatment any contraindication of IFN or amantadin-emergence of drugs adverse reactions, to intending of these criteria 10 case of them had situation for treatment and follow-up. Results: In 10 cases, treatment with IFN  - 2b in doses 3 mu for every square meter of body surface three times in week subcutaneously and cap. Amantadin in doses 100 mg po B.d for 6 months was done and after it, 8 cases were negative for HCV-RNA (8%) and in 6 patients, ALT turned to normal (60%) and in 2 other case ALT decrease to lower than 50% of pretreatment value. None of them showed drug adverse reactions and response to therapy was better in lower ages. No relation between response to therapy and liver hemosiderosis, inflammation and sexuality was found. Conclusion: Combined therapy with IFN and Amantadin is effective in HCV treatment and for lower recurrence, treatment period longer than 24 wk, such as 48 wk is recommendedhttp://journals.tums.ac.ir/PdfMed.aspx?pdf_med=/upload_files/pdf/3244.pdf&manuscript_id=3244Amantadin
spellingShingle Fallahi GHI
Ezadyar M
Fathi A
"Efficacy of interferon and Amantadin for treatment of hepatitis in major thalasemia at Children’s Medical Center, Tehran "
Tehran University Medical Journal
Amantadin
title "Efficacy of interferon and Amantadin for treatment of hepatitis in major thalasemia at Children’s Medical Center, Tehran "
title_full "Efficacy of interferon and Amantadin for treatment of hepatitis in major thalasemia at Children’s Medical Center, Tehran "
title_fullStr "Efficacy of interferon and Amantadin for treatment of hepatitis in major thalasemia at Children’s Medical Center, Tehran "
title_full_unstemmed "Efficacy of interferon and Amantadin for treatment of hepatitis in major thalasemia at Children’s Medical Center, Tehran "
title_short "Efficacy of interferon and Amantadin for treatment of hepatitis in major thalasemia at Children’s Medical Center, Tehran "
title_sort efficacy of interferon and amantadin for treatment of hepatitis in major thalasemia at children s medical center tehran
topic Amantadin
url http://journals.tums.ac.ir/PdfMed.aspx?pdf_med=/upload_files/pdf/3244.pdf&manuscript_id=3244
work_keys_str_mv AT fallahighi efficacyofinterferonandamantadinfortreatmentofhepatitisinmajorthalasemiaatchildrensmedicalcentertehran
AT ezadyarm efficacyofinterferonandamantadinfortreatmentofhepatitisinmajorthalasemiaatchildrensmedicalcentertehran
AT fathia efficacyofinterferonandamantadinfortreatmentofhepatitisinmajorthalasemiaatchildrensmedicalcentertehran